Ann: Kazia paxilisib in Dana Farber study enrols first patient, page-39

that’s right GoFish as if a strategically important tool such as ‘accelerated approval’ would be missed by our highly competent management and science board.

they have this well in hand and will inform the market at the appropriate time - based on key milestones - the focus is as it should be, getting the work done and pulling the drugs through trials and the quickest path to commercialisation.

our science and company boards in combination have literally hundreds of years of pharma and trial experience and have shown time and again their integrity.

these works take time and the experienced here understand the landscape and can see the progress - the recent lic deals alone shows our coming of age as a biotech and managements ability to direct this by process - and by third parties each deal rated by analysts effectively at A+

as always there will be some not happy based on short term observations of SP, fear, uncertainty, doubt - FUD…

there is no doubt in my mind we are setting in place the building blocks to change patients and patients families lives and for incredible rewards for the investors who supported this trial and company building period and have the resolve to stay the course.